Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Current Liabilities (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Total Current Liabilities for 7 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 50.73% to $16.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.4 million through Dec 2025, down 50.73% year-over-year, with the annual reading at $16.4 million for FY2025, 50.73% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $16.4 million at Pliant Therapeutics, down from $17.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $40.0 million in Q3 2024, with the low at $10.2 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $23.4 million, with a median of $23.5 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 106.3% in 2022, then plummeted 55.89% in 2025.
  • Over 5 years, Total Current Liabilities stood at $16.8 million in 2021, then soared by 42.08% to $23.9 million in 2022, then rose by 19.28% to $28.5 million in 2023, then grew by 16.46% to $33.2 million in 2024, then crashed by 50.73% to $16.4 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $16.4 million, $17.6 million, and $20.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.